Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Ro 12-7310. |
| Estradiol | The therapeutic efficacy of Estradiol can be decreased when used in combination with Ro 12-7310. |
| Ethinylestradiol | The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Ro 12-7310. |
| Mestranol | The therapeutic efficacy of Mestranol can be decreased when used in combination with Ro 12-7310. |
| Estradiol cypionate | The therapeutic efficacy of Estradiol cypionate can be decreased when used in combination with Ro 12-7310. |
| Estradiol valerate | The therapeutic efficacy of Estradiol valerate can be decreased when used in combination with Ro 12-7310. |
| Estetrol | The therapeutic efficacy of Estetrol can be decreased when used in combination with Ro 12-7310. |
| Desogestrel | The therapeutic efficacy of Desogestrel can be decreased when used in combination with Ro 12-7310. |
| Megestrol acetate | The therapeutic efficacy of Megestrol acetate can be decreased when used in combination with Ro 12-7310. |
| Levonorgestrel | The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Ro 12-7310. |
| Medroxyprogesterone acetate | The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Ro 12-7310. |
| Norethisterone | The therapeutic efficacy of Norethisterone can be decreased when used in combination with Ro 12-7310. |
| Ethynodiol diacetate | The therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Ro 12-7310. |
| Norgestimate | The therapeutic efficacy of Norgestimate can be decreased when used in combination with Ro 12-7310. |
| Drospirenone | The therapeutic efficacy of Drospirenone can be decreased when used in combination with Ro 12-7310. |
| Cyproterone acetate | The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Ro 12-7310. |
| Gestodene | The therapeutic efficacy of Gestodene can be decreased when used in combination with Ro 12-7310. |
| Hydroxyprogesterone caproate | The therapeutic efficacy of Hydroxyprogesterone caproate can be decreased when used in combination with Ro 12-7310. |
| Dienogest | The therapeutic efficacy of Dienogest can be decreased when used in combination with Ro 12-7310. |
| Norethynodrel | The therapeutic efficacy of Norethynodrel can be decreased when used in combination with Ro 12-7310. |
| Norgestrel | The therapeutic efficacy of Norgestrel can be decreased when used in combination with Ro 12-7310. |
| Gestrinone | The therapeutic efficacy of Gestrinone can be decreased when used in combination with Ro 12-7310. |
| Lynestrenol | The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Ro 12-7310. |
| Chlormadinone | The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Ro 12-7310. |
| Norgestrienone | The therapeutic efficacy of Norgestrienone can be decreased when used in combination with Ro 12-7310. |
| Quingestanol | The therapeutic efficacy of Quingestanol can be decreased when used in combination with Ro 12-7310. |
| Demegestone | The therapeutic efficacy of Demegestone can be decreased when used in combination with Ro 12-7310. |
| Nomegestrol acetate | The therapeutic efficacy of Nomegestrol acetate can be decreased when used in combination with Ro 12-7310. |
| Vitamin A | The risk or severity of adverse effects can be increased when Vitamin A is combined with Ro 12-7310. |
| Valproic acid | Valproic acid may increase the Pseudotumor Cerebri activities of Ro 12-7310. |
| Doxycycline | The risk or severity of pseudotumor cerebri can be increased when Ro 12-7310 is combined with Doxycycline. |
| Clomocycline | The risk or severity of pseudotumor cerebri can be increased when Ro 12-7310 is combined with Clomocycline. |
| Tigecycline | The risk or severity of pseudotumor cerebri can be increased when Ro 12-7310 is combined with Tigecycline. |
| Oxytetracycline | The risk or severity of pseudotumor cerebri can be increased when Ro 12-7310 is combined with Oxytetracycline. |
| Demeclocycline | The risk or severity of pseudotumor cerebri can be increased when Ro 12-7310 is combined with Demeclocycline. |
| Tetracycline | The risk or severity of pseudotumor cerebri can be increased when Ro 12-7310 is combined with Tetracycline. |
| Metacycline | The risk or severity of pseudotumor cerebri can be increased when Ro 12-7310 is combined with Metacycline. |
| Minocycline | The risk or severity of pseudotumor cerebri can be increased when Ro 12-7310 is combined with Minocycline. |
| Rolitetracycline | The risk or severity of pseudotumor cerebri can be increased when Ro 12-7310 is combined with Rolitetracycline. |
| Sarecycline | The risk or severity of pseudotumor cerebri can be increased when Ro 12-7310 is combined with Sarecycline. |
| Eravacycline | The risk or severity of pseudotumor cerebri can be increased when Ro 12-7310 is combined with Eravacycline. |
| Omadacycline | The risk or severity of pseudotumor cerebri can be increased when Ro 12-7310 is combined with Omadacycline. |
| Penimepicycline | The risk or severity of pseudotumor cerebri can be increased when Ro 12-7310 is combined with Penimepicycline. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Ro 12-7310. |
| Lymecycline | The risk or severity of pseudotumor cerebri can be increased when Lymecycline is combined with Ro 12-7310. |
| Palovarotene | The risk or severity of adverse effects can be increased when Ro 12-7310 is combined with Palovarotene. |